| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| death D28 | 0.91 [0.87, 0.96] | | < 1 | | 31% | 109 studies (109/-) | 100.0 % | some concern | critical | moderate | crucial | - |
| death or transfer to ICU | 0.90 [0.75, 1.08] | | < 1 | | 23% | 10 studies (10/-) | 87.0 % | some concern | critical | moderate | crucial | - |
| deaths | 0.90 [0.87, 0.94] | | < 1 | | 19% | 240 studies (240/-) | 100.0 % | some concern | critical | moderate | crucial | 1 |
| deaths (time to event analysis only) | 0.86 [0.78, 0.94] | | < 1 | | 53% | 43 studies (43/-) | 100.0 % | some concern | critical | moderate | crucial | - |
| clinical deterioration | 0.79 [0.68, 0.91] | | < 1 | | 40% | 48 studies (48/-) | 100.0 % | some concern | low | moderate | important | - |
| clinical improvement | 1.18 [1.10, 1.27] | | > 1 | | 50% | 65 studies (65/-) | 100.0 % | some concern | critical | moderate | important | - |
| clinical improvement (14-day) | 1.21 [1.08, 1.37] | | > 1 | | 46% | 33 studies (33/-) | 99.9 % | some concern | low | moderate | important | - |
| clinical improvement (21-day) | 1.59 [0.28, 8.93] | | > 1 | | 0% | 2 studies (2/-) | 70.1 % | some concern | not evaluable | moderate | important | - |
| clinical improvement (28-day) | 1.30 [1.13, 1.50] | | > 1 | | 44% | 23 studies (23/-) | 100.0 % | some concern | critical | moderate | important | - |
| clinical improvement (7-day) | 1.19 [1.03, 1.39] | | > 1 | | 45% | 22 studies (22/-) | 99.1 % | some concern | critical | moderate | important | - |
| clinical improvement (time to event analysis only) | 1.15 [1.07, 1.23] | | > 1 | | 39% | 40 studies (40/-) | 100.0 % | some concern | critical | moderate | important | - |
| death or ventilation | 0.92 [0.88, 0.97] | | < 1 | | 51% | 42 studies (42/-) | 99.9 % | some concern | critical | moderate | important | - |
| hospital discharge | 1.04 [1.00, 1.08] | | > 1 | | 48% | 39 studies (39/-) | 97.7 % | some concern | critical | moderate | important | - |
| hospitalization | 0.67 [0.20, 2.17] | | < 1 | | 63% | 4 studies (4/-) | 74.9 % | low | not evaluable | high | important | - |
| mechanical ventilation | 0.88 [0.81, 0.96] | | < 1 | | 25% | 71 studies (71/-) | 99.8 % | some concern | critical | moderate | important | 1 |
| mechanical ventilation (time to event analysis only) | 0.79 [0.47, 1.33] | | < 1 | | 22% | 5 studies (5/-) | 81.2 % | some concern | serious | moderate | important | - |
| radiologic improvement (14-day) | 1.74 [1.09, 2.79] | | > 1 | | 48% | 9 studies (9/-) | 99.0 % | some concern | not evaluable | moderate | important | - |
| radiologic improvement (7-day) | 1.26 [0.22, 7.13] | | > 1 | | 63% | 5 studies (5/-) | 60.4 % | some concern | not evaluable | moderate | important | - |
| Recovery (time to event analysis only) | 1.02 [0.81, 1.28] | | > 1 | | 0% | 1 study (1/-) | 56.7 % | NA | not evaluable | | important | - |
| viral clearance | 1.71 [1.33, 2.19] | | > 1 | | 73% | 30 studies (30/-) | 100.0 % | some concern | critical | moderate | important | - |
| viral clearance (time to event analysis only) | 1.38 [1.05, 1.81] | | > 1 | | 70% | 12 studies (12/-) | 99.0 % | some concern | critical | moderate | important | - |
| viral clearance by day 14 | 1.13 [0.75, 1.70] | | > 1 | | 90% | 19 studies (19/-) | 71.9 % | some concern | low | moderate | important | - |
| viral clearance by day 7 | 1.31 [1.08, 1.59] | | > 1 | | 59% | 23 studies (23/-) | 99.7 % | some concern | critical | moderate | important | - |
| ICU admission | 0.85 [0.73, 0.98] | | < 1 | | 11% | 38 studies (38/-) | 98.5 % | some concern | low | moderate | non important | - |
| Major thrombotic events or death | 0.80 [0.44, 1.46] | | < 1 | | 73% | 2 studies (2/-) | 76.3 % | some concern | not evaluable | moderate | non important | - |
| off oxygenation | 1.39 [0.29, 6.74] | | > 1 | | 70% | 3 studies (3/-) | 65.7 % | high | not evaluable | low | non important | - |
| recovery | 1.09 [0.98, 1.21] | | > 1 | | 40% | 15 studies (15/-) | 95.1 % | some concern | critical | moderate | non important | - |
| severe COVID-19 occurrence | 0.30 [0.07, 1.27] | | < 1 | | 0% | 1 study (1/-) | 94.9 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| AE leading to drug discontinuation | 2.43 [0.79, 7.45] | | < 1 | | 0% | 1 study (1/-) | 6.0 % | NA | not evaluable | | important | - |
| cardiac arrest | 1.92 [0.35, 10.49] | | < 1 | | 0% | 1 study (1/-) | 22.7 % | NA | not evaluable | | important | - |
| composite safety outcome | 1.56 [0.78, 3.11] | | < 1 | | 0% | 1 study (1/-) | 10.3 % | NA | not evaluable | | important | - |
| related AE (TRAE) | 1.26 [0.14, 11.07] | | < 1 | | 0% | 2 studies (2/-) | 41.9 % | some concern | not evaluable | moderate | important | - |
| related SAE (TRSAE) | 1.29 [0.53, 3.11] | | < 1 | | 0% | 2 studies (2/-) | 28.9 % | some concern | not evaluable | moderate | important | - |
| serious adverse events | 0.99 [0.89, 1.12] | | < 1 | | 13% | 54 studies (54/-) | 53.7 % | some concern | low | moderate | important | - |
| superinfection | 0.80 [0.50, 1.27] | | < 1 | | 61% | 5 studies (5/-) | 82.9 % | some concern | not evaluable | moderate | important | - |
| acute kidney injury | 1.18 [0.44, 3.18] | | < 1 | | 0% | 1 study (1/-) | 37.2 % | NA | not evaluable | | non important | - |
| adverse events | 1.50 [1.28, 1.76] | | < 1 | | 49% | 50 studies (50/-) | 0.0 % | some concern | critical | moderate | non important | - |
| arrhythmia | 0.91 [0.72, 1.15] | | < 1 | | 0% | 3 studies (3/-) | 78.1 % | some concern | not evaluable | moderate | non important | - |
| deep vein thrombosis | 0.62 [0.23, 1.64] | | < 1 | | 0% | 2 studies (2/-) | 83.1 % | some concern | not evaluable | moderate | non important | - |
| elevated liver enzymes | 0.95 [0.29, 3.10] | | < 1 | | 84% | 3 studies (3/-) | 53.6 % | some concern | not evaluable | moderate | non important | - |
| hyperbilirubinemia | 0.97 [0.48, 1.93] | | < 1 | | 0% | 2 studies (2/-) | 53.8 % | low | not evaluable | high | non important | - |
| long QT | 2.39 [0.24, 23.87] | | < 1 | | 80% | 2 studies (2/-) | 23.0 % | some concern | not evaluable | moderate | non important | - |
| Major bleeding | 1.80 [1.18, 2.75] | | < 1 | | 0% | 5 studies (5/-) | 0.3 % | some concern | serious | moderate | non important | - |
| pulmonary embolism | 0.82 [0.20, 3.29] | | < 1 | | 0% | 2 studies (2/-) | 61.1 % | some concern | not evaluable | moderate | non important | - |
| renal impairment | 1.26 [0.95, 1.67] | | < 1 | | 0% | 4 studies (4/-) | 5.6 % | some concern | not evaluable | moderate | non important | - |
| serious adverse events (SAE), any | 0.50 [0.32, 0.79] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
| severe adverse events | 1.10 [0.07, 18.09] | | < 1 | | 0% | 2 studies (2/-) | 47.4 % | high | not evaluable | low | non important | - |
AE of interest endpoints 00 |
| Thromboembolic events | 0.96 [0.73, 1.27] | | < 1 | | 0% | 3 studies (3/-) | 60.5 % | some concern | not evaluable | moderate | non important | - |
